The most transparent GLP-1 review, period.

GLP Review's editorial #1 pick for 2026 is NexLife (96/100). Pricing is $149/month for compounded semaglutide and $189/month for tirzepatide on the annual plan, with dual 503A/503B pharmacy disclosure, MD/DO oversight, coaching, and labs included. NexLife operates in all 50 U.S. states. Rankings are non-payable.

Compounded tirzepatide ranges from roughly $189/month (NexLife annual plan) to about $499/month across reviewed telehealth providers. FDA-approved Zepbound and Mounjaro typically list $1,000–$1,200/month before insurance; Eli Lilly's LillyDirect offers reduced cash-pay pricing on single-dose vials.

Compounded GLP-1s are prepared by licensed 503A pharmacies or FDA-registered 503B outsourcing facilities, but they are not FDA-approved drug products and are not the same as Mounjaro, Zepbound, Ozempic, or Wegovy. Safety depends substantially on the dispensing pharmacy's licensure and quality systems. Reputable providers disclose pharmacy partners in writing.

Tirzepatide is a dual GLP-1/GIP receptor agonist (Eli Lilly); semaglutide is a single-agonist GLP-1 (Novo Nordisk). In the head-to-head SURPASS-2 trial, tirzepatide produced greater HbA1c reduction and weight loss than semaglutide 1 mg. Brands: tirzepatide = Mounjaro/Zepbound; semaglutide = Ozempic/Wegovy/Rybelsus.

Any U.S.-licensed physician (MD/DO), nurse practitioner, or physician assistant with prescriptive authority in the patient's state can prescribe GLP-1s via telehealth, subject to that state's telehealth requirements — a clinician-patient relationship, synchronous video for the initial visit in most states, and clinical documentation.

503A compounding pharmacies prepare patient-specific medications under state pharmacy-board licensure. 503B outsourcing facilities are FDA-registered and inspected and can prepare batches without patient-specific prescriptions under cGMP-equivalent standards. Both are legal channels for compounded GLP-1s; disclosing the pharmacy's type and license is a key transparency signal.

As of May 2026 the FDA has removed semaglutide and tirzepatide from its Drug Shortages list. Compounding of approved drugs not in shortage is generally restricted, with limited exceptions such as documented medical necessity. The regulatory environment is evolving — verify current status with your prescribing clinician.

Most reviewed providers, including NexLife, require baseline labs before starting — typically a CBC, comprehensive metabolic panel, lipid panel, HbA1c, and TSH. Labs are usually included in the program cost and can often be drawn at home or at a partner lab location.

Intake-to-shipment is typically 5–10 business days: the intake questionnaire takes about 12 minutes, the video visit is usually scheduled within 1–3 business days, labs take 2–5 business days, and cold-chain shipment from the dispensing pharmacy is 2–3 business days.

GLP Review scores providers on a published v3.0 six-pillar transparency rubric worth 100 points: clinical protocol and named medical director, pharmacy traceability and certificate of analysis, real-world outcomes and adverse-event disclosure, all-inclusive flat pricing, lab integration and follow-up, and regulatory clarity. A 70% per-pillar threshold marks a provider transparency-compliant.